Iovance, AbCellera, and CrowdStrike Hit Yearly Highs

Three firms across biotech and security sectors reached 52-week peak valuations following operational updates.

Updated on Sept. 30, 2026 in Biotech

Isometric editorial illustration featuring a detailed gear assembly and a silicon wafer, representing industrial and technological growth. — Iovance Biotherapeutics, AbCellera Biologics, and CrowdStrike Holdings reached 52-week high valuations on September 30, following strategic updates to their commercial and AI integration programs. AI Illustration. Upload story photo >

Live Poll

Do you believe analyst upgrades are a reliable signal to purchase stocks right now?

Iovance Biotherapeutics, AbCellera Biologics, and CrowdStrike Holdings each reached 52-week high share prices on September 30, 2026. These gains followed announcements regarding updated revenue forecasts, clinical program ratings, and new platform integrations.

Why it matters

Market enthusiasm reflects confidence in commercial demand for Iovance's Amtagvi therapy and the integration of security platforms with AI tools. These movements underscore how specialized clinical performance and AI marketplace expansion are currently driving investor valuations.

Iovance raised its 2026 revenue forecast to a range of $410 million to $420 million, citing increased demand for its Amtagvi therapy. Meanwhile, AbCellera saw analyst coverage upgraded by JPMorgan to an Overweight rating with a $17 price target based on ABCL635 program results.

The players

Iovance Biotherapeutics

A biotechnology firm focused on cell therapies for cancer using tumor-infiltrating lymphocytes.

AbCellera Biologics

A drug discovery technology company that develops platforms for antibody therapeutic research.

CrowdStrike Holdings

A cybersecurity firm that operates the Falcon platform, a cloud-native solution for endpoint protection.

JPMorgan

A global financial services institution that provides equity research and market coverage.

The details

Iovance is scaling commercial operations for Amtagvi, a tumor-infiltrating lymphocyte therapy where a patient's own immune cells are harvested and expanded for cancer treatment. CrowdStrike announced it is bringing its Falcon cloud-based security platform to the OpenAI Marketplace, a digital store for AI-powered agents and tools. Investors anticipate that the rising deployment of automated AI agents will generate sustained demand for security infrastructure capable of protecting these new workflows.

September 29, 2026: Retail sentiment turned bullish for Iovance and AbCellera.
September 30, 2026: Iovance, AbCellera, and CrowdStrike reached 52-week stock highs.

The Tech Race

The move by CrowdStrike to integrate with the OpenAI Marketplace marks a shift toward embedding security tools directly into AI-native infrastructure. This trajectory aligns with industry competition to capture the security requirements of new enterprise AI agent workflows.

Users of security software can expect CrowdStrike's Falcon platform to become accessible through the OpenAI ecosystem. For healthcare stakeholders, Iovance's updated revenue outlook suggests an expanded capacity to deliver Amtagvi therapy to patients needing specialized cancer treatment.

The takeaway

The dual rise of biotech commercial performance and security platform expansion highlights current market focus on AI-driven workflows and therapeutic scale. Investors should watch for H.C. Wainwright's further updates regarding their $20 price target for Iovance.